Journal articlePharmaceutics2022

Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment.

DOI 10.3390/pharmaceutics14061202 ↗ PubMed Central open-access subset, retrieved 5 November 2026

Journal: Pharmaceutics
Published: 5 June 2022
Citations: 8
Type: Article
License: cc by
Full text: Open access, reuse-licensed (cc by)

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.

Try